XXX. call positive Day for we'll Mike outcome review R&D preparations our open the our clinical VTL-XXX I'll financial XXXX comments Then begin on from for the it other everyone with potential activities, status of Al. our our of trial, second discuss quarter finally, and results. Q&A. recap recent our R&D some second introductory afternoon, I'll to today's update some to Thanks On And call. up Good welcome Analyst and call,
subject and alcoholic pivotal our know, to sAH. results topline evaluating announcing very Phase are probably VTL-XXX, you ELAD for hepatitis severe close to III or we As trial
to next press discuss keep which announced second topline a conference in us expect the call track on be will half the results. the in to to release results We and by announce be days, results database month via will followed XX next of the lock September. Topline
part for our database As overall the to a the of a check have At reminder, survival, outcome XXX. assuming outcome to plan that the consultants multitude of then the it this population. primary analytical consultants. and XXX public. want These using intent of the to of form will will data, includes request we are of not and the the topline we After results database us analyses analysis the outside to package know over which is the to present the FDA, data. emphasize endpoint results end of a turn according lock, the not then analysis numerous Kaplan-Meier announce will steadfastly process, analysis perform a to only as blinded these process remained the BLA couple survival takes is assessing outside statistician treat This do positive. we but the to I And also predefined done. will quality statistical as to statistical anticipated of weeks we of
much earlier, mentioned this momentous event company. to looking the forward we Needless the As second say, is of are announcement half for for to anticipated currently September. very this
outside Hepatology, company presented. in of Lecturer School, Medical were headquarters sAH. Pyrsopoulos, Clinical we presentation Day a gave in Gastroenterology hepatitis Honorary Dr. our clinical the in Imperial There front, on addition Diego. a and survival severe the of London, there number fact it made an the College Registrar how his generated held is characterizing experience alcoholic expense. existing of Jersey demonstrated from days. clinical of ELAD alcoholic of external and just Gastroenterology are with May among and R&D field have The pathophysiology two first data limited experts Dr. highlighted And the presented also The Vital XX Numbers discussed hypothesize R&D experts have option we pain, hepatitis mechanism data to extensive and in-vitro key Stephen then Atkinson, benefit background in that reviewed our R&D New of Nick Hepatology Day. and alcoholic An takeaways XX, of Specialist action. clinical clear Analyst presentations, Also for Rutgers Analyst of at Chief sAH. the in-vivo On disease R&D San and Therapies on and beyond terms mortality experts team treatment hepatitis. treatments, none even
reporting has our proud in are that considerable we work area. this support completed We very to cell findings forward therapy. look that And future been
ELAD Our shape design us believe treat we to Chief how of Rob on trials presentation let Officer, prior is a and clinical this made XXX. Technical what appropriate Ashley population with from our learnings how the
the Pyrsopoulos section An be from presentation. these thank We'd We of submission. who found participated for some slide will to that materials. participating positive for that topline highly also Investor you in informative person. in discussed Relations event. opportunity attractive of we traveled the this like E.U. belief we these several of attend have reinforced our our and in Dr. how own can our XXX thank in and target and development with event Finally, associated webcast who successful highly to commercial this BLA on We archive of the a commercialize event our a can website clinical Atkinson is we and like predictions Overall, along from to the the encourage plans to U.S. our and if we the ELAD analysts successful, in results review the
Next, liver program. a perfusion our quick update on
We at the for to the CGM As been the this potential number might combination of Birmingham condition of you for body U.K. we may temperature maintain have prior are VTL-XXX livers. and transplant [ph]. evaluate increase improve in in we recall, Philadelphia donor use with the the livers to substances Drexel mixture in by designed of organs that University the with working machines call produced the to the And of to CGM marginal University available cells hopeful transplantation. of mixture
We order XXX split the MGH are a Vivo to model Ex accelerating BLA entering we for commercialization. although solutions topline and from continue be activities with MGH. undertaking further With regard organization, to important it's our hope after hiring a months preparations include pleased We We at more to realistic BLA look future. results. San as understand to quickly assuming program for of perfusion critical we on collaboration work to to the profusion a we a the here ELAD own explore forward of important BLA capitalize results, currently advance for Preparing current preparations in submission, These or why, for as a results what submission will definitive for comparison To by in positive use in clinical BLA more will program have manufacture In CGM in any XX into recently extended we prepare BLA to cell recall huge liver this the General is after submission believe announce preparations CXA the our possible in the time submission Massachusetts future. results. Hospital with facility topline by is positive developed XXX, that we frame. reporting data submitting research this to on trial Diego. cartridges we're
for has our facility two product occupied, been years, last manufacturing clinical the For trials. fully this
processes focus validation product prior commercial we and part facilities. of the data which to new However and from equipment BLA is includes to preparing manufacturing generating scale need submission, for manufacture, facility related commercial
be to is and modular shortest will at this of that manufacturing we for result processes achieve. the development through of goal We installed we highest which submission ELAD Also possibly runs plan. on some BLA be time on full new risk light a shed and submission need BLA validated in approval modules but to consider, accepted the success a our following hope is in the will While required be prepare consuming what can manufacturing our time for as first unavoidable likelihood part is submission. nature, and the
President towards leadership to hiring additions to Gary as management Genentech in with guiding companies front, the Vital evolve a such team role needed Neumann recently biotech added will critical as will the a that play We On Novartis. to be Vice BLA has Quality. the stage extensive critical Gary we experience we're submission. as Gary Therapies the team identify organization. and working commercial key
U.S. we're for we pursuing experts consultants to to Looking a ELAD. outside of we commercialization ahead, our determine of will development journal clinical soon key might broader leadership alcohol We're the On reach of lay patients. effort in the that including expand promising of roles to This well to in results. sAH publication front, of a market positive will initiatives recent need the with launch for work sAH number as of the candidates able of the we get the number prior and reviewed a size working best field believe peer be a potential in on a [ph] be these disease understanding that the how are fill we contact when validates in with groundwork a
potentially continue relatively the when adjusted ELAD value lifesaving pairs qualities attractive the therapy we this to evaluate we for therapies. offer We to have system. life may the of that believe ELAD's ratios will life demonstrate a favorable, positive quality a the believe results or particularly We reimbursement other event effectiveness as that build proposition healthcare could in implication that from positive ELAD population. In compared young to cost extending XXX, believe since highly quite years out be will
our we in confirm key lifesaving strategies. due ELAD. as the these To the around to hear In It's seek to of with thinking from to great of date, experts our have the very potentially nature sAH. meeting excellence been to from been experts directly is feedback our treatment optimize to encouraging centers them the of for addition, field approach launch we
the the of be characterization serious related prevalent and trial. is to topline continue sAH company this population. raise this alcohol and of disease is of a focused the on awareness data the nature of around There awareness patient will for will liver already We growing raising visibility how XXX positive of Much the appropriate becoming.
those in article the alcohol XXs. the XXXX increase consumption and States deaths particularly related Just sharp last to their in in XXs published United in and documented BMJ among XXXX the an between
consumption likely young implications the as failure While disease, well. chronic acute for that study liver increased focused among alcohol on liver forms has of
a only is as So to event the positive in results This snapshot we're prepared activities these from on it's our undertaken about near to over We our of I'll activities educate moving problem. of second trial. call VTL-XXX the forward for more future. the important the Mike the in public clinical financial results. growing this turn report we of hope for to discussion a quarter
